Equities

Senzime AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Senzime AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)4.39
  • Today's Change-0.11 / -2.44%
  • Shares traded22.89k
  • 1 Year change-21.61%
  • Beta0.4874
Data delayed at least 15 minutes, as of Mar 02 2026 08:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.

  • Revenue in SEK (TTM)104.02m
  • Net income in SEK-137.42m
  • Incorporated1999
  • Employees50.00
  • Location
    Senzime AB (publ)Verkstadsgatan 8, hus 1UPPSALA 753 23SwedenSWE
  • Phone+46 18515640
  • Fax+46 18515630
  • Websitehttps://senzime.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ortoma AB77.19m-7.52m416.18m10.00--2.6479.705.39-0.2027-0.20272.084.450.42433.9539.137,530,537.00-4.13-9.37-4.45-10.4341.26158.24-9.74-78.903.02--0.00--28.77--46.83---0.5751--
Mentice AB274.49m-43.31m431.73m121.00--3.43--1.57-1.68-1.6810.524.480.96631.603.942,095,328.00-15.25-6.64-31.60-11.9190.4084.80-15.78-8.530.845-30.100.116--6.1114.22-553.89--32.86--
Q linea AB11.10m-182.48m465.77m83.00--1.38--41.97-35.87-35.871.3117.840.04290.40062.90---70.50-76.00-101.81-93.84-15.26-145.47-1,644.30-2,820.5110.04-30.480.017--369.86114.7515.86---34.47--
Modulight Oyj75.41m-49.11m506.44m71.00--1.06--6.72-0.12-0.120.18741.050.1341-1.014.54---8.73-11.40-9.39-12.14132.06125.90-65.10-126.563.79--0.0588--72.63-6.8228.59--15.83--
Bactiguard Holding AB228.77m-7.84m540.16m153.00--1.9413.772.36-0.2238-0.22386.538.990.3813.446.911,495,216.00-1.31-8.02-1.86-10.1363.7848.56-3.43-25.101.38-0.33870.3410---12.644.2273.69---17.92--
Gentian Diagnostics ASA167.55m12.58m578.28m63.0046.702.9727.233.450.84590.845911.3513.290.72311.566.36--5.43-0.04836.25-0.05555.6447.277.51-0.07883.81--0.0866--16.0722.75-70.73--10.72--
Optomed Oyj182.36m-70.83m612.18m111.00--2.39--3.36-0.3374-0.33740.86881.120.53632.875.07154,009.00-20.83-17.19-25.75-20.6963.6064.81-38.85-34.212.03-8.910.1014--13.675.61-21.83--5.30--
BioPorto A/S52.20m-123.91m639.68m48.00--11.70--12.26-0.1973-0.19730.0830.07740.41322.554.69962,131.60-98.08-65.22-133.92-88.7463.9064.15-237.40-222.221.71--0.1916--17.076.36-21.15---20.56--
Nanexa AB36.15m-11.39m655.87m15.00--6.39570.3218.14-0.0724-0.07240.22550.62370.314416.225.232,409,933.00-9.90-31.63-12.96-38.7886.0296.94-31.50-218.011.51-3.210.0109--48.3972.5054.27--3.54--
Senzime AB (publ)104.02m-137.42m707.47m50.00--2.32--6.80-0.9396-0.93960.70731.940.26192.617.48---34.60-36.25-37.96-39.0233.3524.11-132.11-271.043.04-7.450.044--77.8961.95-15.74--123.16--
OssDsign AB180.16m-50.99m715.75m32.00--2.31--3.97-0.5493-0.54932.062.800.51090.36726.955,629,938.00-14.46-25.42-16.05-28.5996.2985.57-28.30-82.426.33-13.770.0044--34.5148.59-2.68--24.28--
Omda AS450.83m-28.74m773.95m260.00--23.9527.501.72-1.51-1.5123.591.630.679326.5921.701,772,075.00-4.33-5.14-5.39-6.6393.6991.09-6.37-10.320.64830.52810.9359--3.4515.80-163.95---15.57--
Nexstim Oyj107.36m-3.02m823.35m40.00--24.18116.287.67-0.042-0.0421.470.44260.85530.56134.66251,616.80-2.40-12.40-4.17-20.7694.3695.09-2.81-16.291.080.78350.6002--20.5521.1432.79--15.13--
Sedana Medical AB (publ)200.23m-59.24m873.17m122.00--0.9694--4.36-0.5964-0.59642.029.070.20291.387.181,641,205.00-6.00-5.16-6.33-5.4371.2770.03-29.59-32.032.66-1.280.0052--12.017.15-455.03---5.91--
C Rad AB442.00m10.40m875.25m110.0085.712.5942.281.980.31040.310413.2510.280.89284.292.404,018,182.002.107.012.999.8151.9546.992.357.122.771.550.02642.44-5.7814.80-81.40-6.08----
Data as of Mar 02 2026. Currency figures normalised to Senzime AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

21.24%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Sep 20258.19m5.21%
Handelsbanken Fonder ABas of 31 Dec 20246.19m3.94%
Unionen (Investment Management)as of 30 Sep 20256.08m3.87%
Swedbank Robur Fonder ABas of 30 Jan 20264.78m3.04%
Teknik Innovation Norden Fonder ABas of 30 Sep 20254.52m2.87%
Amundi Asset Management SASU (Investment Management)as of 31 Dec 20251.39m0.89%
Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Nov 20251.06m0.67%
Storebrand Asset Management ASas of 31 Jan 2026494.20k0.31%
SEB Funds ABas of 30 Jan 2026448.52k0.29%
Skandia Investment Management ABas of 28 Nov 2025241.01k0.15%
More ▼
Data from 23 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.